Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

Documenti analoghi

• Comparative efficacy and safety of dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes mellitus: A network meta‐analysis
  di: Gongquan Wang, et al.
  Pubblicazione: (2024)
• A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial
  di: Qinghua He, et al.
  Pubblicazione: (2024)
• Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
  di: Hideaki Hashimoto, et al.
  Pubblicazione: (2024)
• Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
  di: Estela Lajthia
  Pubblicazione: (2019)
• Biotransformation and disposition characteristics of HSK7653 , a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes
  di: Yi‐cong Bian, et al.
  Pubblicazione: (2024)